Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Wednesday 15 November, 2017

Oxford BioDynamics

Data at FNIH Biomarker Consortium Cancer Meeting

RNS Number : 4937W
Oxford BioDynamics PLC
15 November 2017
 

 

 

15 November 2017

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics presents latest immunotherapy data at the NIH Biomarker Consortium Cancer Steering Committee Annual Symposium, in Washington, DC

 

EpiSwitchTM technology shows consistent profile of predictive biomarkers for response to immune checkpoint inhibitor therapy

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, presented its latest results at the annual meeting of the Foundation for National Institute for Health (FNIH) Biomarker Consortium Cancer Steering Committee, held in Washington, DC on 6-7 November 2017.

 

In the session dedicated to immune-oncology biomarkers, Dr A. Akoulitchev, Chief Scientific Officer of OBD, presented the results from three independent studies which showed a consistent profile of epigenetic markers for response to immune checkpoint inhibitor therapies, including anti-PD-L1 therapy Keytruda (Pembrolizumab) and several other anti-PD-L1 assets in two disease indications.

 

Blind validation of an independent cohort of base line patients treated with an anti-PD-L1 therapeutic showed that OBD's EpiSwitch™ technology could predict response to treatment with a 83% positive predictive value (PPV). The biological relevance of identified epigenetic regulatory biomarkers for immunotherapy was strongly supported by their role in T-cell reinvigoration, survival, and proliferation to tumour burden.

 

It was also shown that a sub-group of the predictive EpiSwitch™ markers for response to treatment, identified and verified in over 57 patients, were associated to genes which are downstream of Interferon gamma stimulation. Another subgroup of biomarkers revealed high concordance with regulatory controls of MHC II receptors, known to play critical role in response to anti-PD-1 therapy.  Full scope of the patient cohorts analysed by OBD will exceed 180 patients.

 

Further implications of EpiSwitchTM based approaches to patient stratifications were also discussed, including exclusion of patients with hyper progression and other side effects to immunotherapy.

 

The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, preventive medicine, and medical diagnostics.

 

The Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organisations. OBD is represented at the Steering Committees covering Cancer, Inflammation & Immunity, and Neuroscience by Dr Claudio Carini, an Advisor to OBD and a member of the Company's Scientific Advisory Panel.

 

Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:

 

"We are delighted with the progress and consistent quality of biomarker data that our EpiSwitch™ platform has been able to deliver in these immunotherapy studies. The immunotherapy biomarker programme has developed into a high value area of interest for OBD and we are committed to offering quick and robust practical solutions for patient stratifications for all the therapy programmes we are working on.

 

We have been actively expanding our intellectual property footprint, and with our technology demonstrating consistent practical solutions, we see immunotherapy as a strategic line of biomarker development for our Company, which we believe has the potential to further improve clinical outcomes and the standard of patient care in this area.   

 

We believe that being among a network of many reputable companies and institutions will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for chromosome conformations and biomarkers in genome architecture."

 

For further details contact:

 

Oxford BioDynamics Plc

 

+44 (0)1865 518910

Christian Hoyer Millar, CEO

 

 

Paul Stockdale, CFO

 

 

 

 

 

FTI Consulting  

 

+44 (0)20 3727 1000

Financial Public Relations Advisor

 

 

Julia Phillips

 

 

Brett Pollard

 

 

Natalie Garland-Collins

 

 

 

 

 

Stifel Nicolaus Europe Limited

 

+44 (0)20 7710 7600

Nominated Advisor and Broker

 

 

David Arch

 

 

Jonathan Senior

 

 

Peter Lees

 

 

Ben Maddison

 

 

 

 

 

Shore Capital

 

+44 (0)20 7408 4090

Joint Broker 

 

 

Stephane Auton

 

 

Edward Mansfield

 

 

 

 

 

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLBDBDGBBGRS

a d v e r t i s e m e n t